Theranexus SA (ALTHX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.305x

Based on the latest financial reports, Theranexus SA (ALTHX) has a cash flow conversion efficiency ratio of -0.305x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-883.76K ≈ $-1.03 Million USD) by net assets (€2.90 Million ≈ $3.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Theranexus SA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Theranexus SA - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Theranexus SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Theranexus SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Theranexus SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Royal Road Minerals Ltd V:RYR	-0.133x
Regional Express Holdings Ltd AU:REX	0.063x
Centara Hotels & Resorts Leasehold Property Fund BK:CTARAF	0.025x
Flagship Minerals Ltd AU:FLG	-0.163x
Hanil Forging Industrial Co. Ltd KQ:024740	0.039x
Equus Energy Ltd AU:EQU	-0.161x
Daekyo KO:019680	0.035x
Polychem Indonesia Tbk JK:ADMG	-0.015x

Annual Cash Flow Conversion Efficiency for Theranexus SA (2015–2025)

The table below shows the annual cash flow conversion efficiency of Theranexus SA from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see ALTHX company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€2.90 Million ≈ $3.39 Million	€-883.76K ≈ $-1.03 Million	-0.305x	-114.98%
2024-12-31	€-1.66 Million ≈ $-1.94 Million	€-3.37 Million ≈ $-3.94 Million	2.033x	+171.04%
2023-12-31	€2.22 Million ≈ $2.60 Million	€-6.36 Million ≈ $-7.43 Million	-2.862x	-205.08%
2022-12-31	€5.73 Million ≈ $6.70 Million	€-5.37 Million ≈ $-6.28 Million	-0.938x	-52.84%
2021-12-31	€10.18 Million ≈ $11.90 Million	€-6.25 Million ≈ $-7.31 Million	-0.614x	-11.20%
2020-12-31	€10.28 Million ≈ $12.02 Million	€-5.68 Million ≈ $-6.64 Million	-0.552x	-8.61%
2019-12-31	€9.98 Million ≈ $11.66 Million	€-5.07 Million ≈ $-5.93 Million	-0.508x	-21.77%
2018-12-31	€13.41 Million ≈ $15.68 Million	€-5.60 Million ≈ $-6.54 Million	-0.417x	-312.77%
2017-12-31	€18.71 Million ≈ $21.87 Million	€-1.89 Million ≈ $-2.21 Million	-0.101x	+99.38%
2016-12-31	€89.85K ≈ $105.05K	€-1.47 Million ≈ $-1.72 Million	-16.406x	-3069.12%
2015-12-31	€1.68 Million ≈ $1.96 Million	€-867.96K ≈ $-1.01 Million	-0.518x	--

About Theranexus SA

PA:ALTHX France Biotechnology

Market Cap

$58.92 Million

€50.40 Million EUR

Market Cap Rank

#22310 Global

#350 in France

Share Price

€3.49

Change (1 day)

-6.18%

52-Week Range

€0.76 - €4.37

All Time High

€22.70